465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552
https://www.admabiologics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 624
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Adam S. Grossman | Co-Founder, President, CEO, Interim CFO & Director | 1,59M | S.O. | 1977 |
Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder & Vice Chairman of the Board | 90k | S.O. | 1948 |
Ms. Kaitlin Kestenberg | COO & Senior VP of Compliance | S.O. | S.O. | 1987 |
Mr. Drew Pantello | Vice President of Marketing & Corporate Development | S.O. | S.O. | S.O. |
Ms. Cindy Petersen | Executive Director of Human Resources | S.O. | S.O. | S.O. |
Mr. Skyler Bloom | Senior Director of Business Development & Corporate Strategy | S.O. | S.O. | S.O. |
Mr. Brad Tade | Vice President of Financial Operations | S.O. | S.O. | S.O. |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
L’ISS Governance QualityScore de ADMA Biologics, Inc. en date du 1 mai 2024 est 7. Les scores principaux sont Audit : 8; Société : 7; Droits des actionnaires : 8; Compensation : 7.